Quintessence Biosciences, Inc.
3300 Commercial Avenue
Madison, Wisconsin 53714 USA
Phone: +1-608.441.2950
Fax: +1-608.441.2952
Main Image



To sign up for news alerts about Quintessence Biosciences, please fill out this form:

Press Releases
15 June 2012
Quintessence Biosciences Meeting with Partners at 2012 BIO International Convention (PDF)
31 May 2012
Quintessence Biosciences Presents on Phase I trial of Human Ribonuclease Variant, QBI-139, at the American Society of Clinical Oncology Annual Meeting (PDF)
19 April 2012
Quintessence Biosciences Selected for Buzz of BIO at 2012 BIO International Convention (PDF)
12 April 2012
Quintessence Biosciences Announces Election of Walter Dewey to Board of Directors (PDF)
30 March 2012
Quintessence Biosciences Presents Results for Combination Studies of Clinical Stage Ribonuclease QBI-139 at AACR Meeting (PDF)
15 January 2010
Quintessence Biosciences to Present at Keystone Symposia’s RNA Silencing Conference (PDF)
13 January 2010
Quintessence Biosciences Announces Expansion to The University of Texas M. D. Anderson Cancer Center of the Cancer Clinical Trial for QBI-139 (PDF)
6 January 2010
Quintessence Biosciences to Present at OneMedForum 2010 (PDF) See an interview with Laura Strong, President and COO of Quintessence, at the OneMedForum 2010 (link)
8 December 2009
Quintessence President and COO, Laura Strong, Talks with Joan Gillman and Jody Glynn Patrick from In Business with Joan and Jody on Madison WTDY 1670 (link)
13 November 2009
Quintessence Biosciences to Present QBI-139 Data at International Cancer Conference(PDF)
3 September 2009
Quintessence Gets Support from the National Cancer Institute for Next Generation EVade™ RNases (PDF)
26 March 2009
Patients Now Enrolling in Phase I Human Trial for Quintessence Biosciences Cancer Drug, QBI-139 (PDF)
5 December 2008
Quintessence Biosciences Cancer Drug, QBI-139, Clears FDA Review to Start Phase I Human Trial (PDF).
23 October 2008
Quintessence Biosciences Present Efficacy Data for Next Generation EVade™ Ribonucleases at Cancer Meeting (PDF)
6 October 2008
Federal Contract Awarded to Quintessence Biosciences (PDF) Funding will support development of Next Generation EVade™ Ribonuclease Drug Candidates.
14 April 2008
Quintessence Biosciences, Inc. Presents IND-Enabling Toxicology Data at Cancer Meeting (PDF) At the Annual Meeting of the American Association for Cancer
Research today, Quintessence Biosciences presented the results of the IND-enabling toxicology
studies for the Company’s lead cancer drug candidate, QBI-139.
5 February 2008
Althea Technologies Chosen by Quintessence Biosciences to Produce Lead Protein Oncology Drug (PDF) Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today that is has been awarded a contract from Quintessence Biosciences under a manufacturing supply agreement to produce the firm’s first drug candidate.
30 November 2007
Quintessence Biosciences, Inc. Announces Award of Two Federal Grants to Support Development of EVade™ Ribonuclease Products (PDF) The National Cancer Institute awarded Quintessence Biosciences two Phase 1 Small Business Innovation Research grants.
22 October 2007
Quintessence Biosciences, Inc. Presents Additional Data on Lead Candidate (PDF) Quintessence Biosciences presented information about the company’s lead candidate QBI-139 at the International Conference on Molecular Targets and Cancer Therapeutics - the premier international meeting featuring novel cancer therapeutics.
16 April 2007
Quintessence Biosciences, Inc. Presents Pre-clinical Toxicology Data at Cancer Meeting (PDF) At the Annual Meeting of the American Association for Cancer Research today, Quintessence Biosciences presented pre-clinical toxicology data on the performance of the Company’s lead cancer drug candidate, QBI-139 for treatment of patients with solid tumors. 
8 February 2007
Quintessence Biosciences, Inc. Names Laura Strong, Ph.D. as President (PDF) Quintessence Biosciences today announced the appointment of Laura Strong, Ph.D. to the position of the Company’s President and Chief Operating Officer.
9 November 2006
Quintessence Biosciences Confirms Selection of EVade™ Ribonuclease Cancer Treatment for Late Stage Pre-Clinical Studies (PDF) Quintessence Biosciences, Inc. today confirmed the selection of a compound from its proprietary EVade™ Ribonuclease program for advancement to pre-clinical testing and human clinical trials.
19 April 2005
Quintessence Biosciences Announces Start of Non-Clinical Studies on Lead Candidate QBI-139 at the 2005 Annual Meeting of the American Association of Cancer Research (PDF)
© 2015 Quintessence Biosciences, Inc. .
Home | About Us | Product Pipeline | Technology | News | Contact | Search